Moderna (MRNA) Stock Drops 4.6% Despite Groundbreaking Cancer Vaccine Breakthrough
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
The US companies Moderna and Merck caused a stir with a therapy against black skin cancer. Biontech lags behind in the development of mRNA vaccines.
Moderna (MRNA) Stock Drops 4.6% Despite Groundbreaking Cancer Vaccine Breakthrough
Key Takeaways In collaboration with Merck, Moderna’s personalized mRNA cancer treatment, intismeran autogene, demonstrated a 49% reduction in melanoma recurrence across a pivotal study involving more than 1,000 participants—representing the first therapeutic cancer vaccine success in over a century. Shares of MRNA began Friday’s session at $142.77, sliding 4.6%, though the stock has climbed over 130% since the groundbreaking vaccine data was di…
Another key step towards personalized medicine in cancer treatment has been taken. A personalized mRNA cancer vaccine being developed by Moderna and Merck has met key milestones in a Phase 3 clinical trial conducted in melanoma patients.
An experimental vaccine developed in partnership with the US pharmaceuticals Moderna and MSD presented promising results in the fight against melanoma in patients with a high risk of recidivism.The data, released by the companies through a press release, indicate that the combination of the immunosorbent with a conventional medicine can prolong the lives of patients and contain the advancement of the tumor.The phase 3 study — final testing stage…
The results of a phase 3 trial indicate that messenger RNA therapy intismeran autogene, combined with pembrolizumab
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
